48 related articles for article (PubMed ID: 12361388)
1. Destruxin E backbone modification effects on osteoclast Morphology: Synthesis and SAR study of N-Desmethyl and N-Methyl analogs.
Sato H; Murase H; Ishida Y; Sugiyama H; Uekusa H; Nakagawa H; Yoshida M; Doi T
Bioorg Med Chem; 2024 Jun; 108():117777. PubMed ID: 38852256
[TBL] [Abstract][Full Text] [Related]
2. Taming Conformational Heterogeneity on Ion Racetrack to Unveil Principles that Drive Membrane Permeation of Cyclosporines.
Limbach MN; Lindberg ET; Olivos HJ; van Tetering L; Steren CA; Martens J; Ngo VA; Oomens J; Do TD
JACS Au; 2024 Apr; 4(4):1458-1470. PubMed ID: 38665661
[TBL] [Abstract][Full Text] [Related]
3. Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models.
Francavilla F; Sarcina F; Schepetkin IA; Kirpotina LN; Contino M; Schirizzi A; De Leonardis G; Khlebnikov AI; D'Alessandro R; Quinn MT; Lacivita E; Leopoldo M
Eur J Med Chem; 2023 Dec; 261():115854. PubMed ID: 37839346
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil chemoattractant receptors in health and disease: double-edged swords.
Metzemaekers M; Gouwy M; Proost P
Cell Mol Immunol; 2020 May; 17(5):433-450. PubMed ID: 32238918
[TBL] [Abstract][Full Text] [Related]
5. Targeting Endothelial Barrier Dysfunction Caused by Circulating Bacterial and Mitochondrial N-Formyl Peptides With Deformylase.
Martinez-Quinones P; Komic A; McCarthy CG; Webb RC; Wenceslau CF
Front Immunol; 2019; 10():1270. PubMed ID: 31244835
[TBL] [Abstract][Full Text] [Related]
6. Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma.
Locke LW; Kothandaraman S; Tweedle M; Chaney S; Wozniak DJ; Schlesinger LS
Tuberculosis (Edinb); 2018 Jan; 108():201-210. PubMed ID: 29623875
[TBL] [Abstract][Full Text] [Related]
7. The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition.
He HQ; Ye RD
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335409
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.
Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
Int Immunopharmacol; 2016 Aug; 37():43-58. PubMed ID: 26382576
[TBL] [Abstract][Full Text] [Related]
9. ATP Binding Cassette Transporter Mediates Both Heme and Pesticide Detoxification in Tick Midgut Cells.
Lara FA; Pohl PC; Gandara AC; Ferreira Jda S; Nascimento-Silva MC; Bechara GH; Sorgine MH; Almeida IC; Vaz Ida S; Oliveira PL
PLoS One; 2015; 10(8):e0134779. PubMed ID: 26258982
[TBL] [Abstract][Full Text] [Related]
10. V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins.
Zhou C; Zhou Y; Wang J; Feng Y; Wang H; Xue J; Chen Y; Ye RD; Wang MW
Biochem J; 2013 Apr; 451(2):245-55. PubMed ID: 23373827
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B.
Morohashi K; Sahara H; Watashi K; Iwabata K; Sunoki T; Kuramochi K; Takakusagi K; Miyashita H; Sato N; Tanabe A; Shimotohno K; Kobayashi S; Sakaguchi K; Sugawara F
PLoS One; 2011 Apr; 6(4):e18285. PubMed ID: 21559518
[TBL] [Abstract][Full Text] [Related]
12. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
Galat A; Bua J
Cell Mol Life Sci; 2010 Oct; 67(20):3467-88. PubMed ID: 20602248
[TBL] [Abstract][Full Text] [Related]
13. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.
Ye RD; Boulay F; Wang JM; Dahlgren C; Gerard C; Parmentier M; Serhan CN; Murphy PM
Pharmacol Rev; 2009 Jun; 61(2):119-61. PubMed ID: 19498085
[TBL] [Abstract][Full Text] [Related]
14. Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.
Rittner HL; Hackel D; Voigt P; Mousa S; Stolz A; Labuz D; Schäfer M; Schaefer M; Stein C; Brack A
PLoS Pathog; 2009 Apr; 5(4):e1000362. PubMed ID: 19343210
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4613-28. PubMed ID: 12361388
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
17. The potent immunosuppressive cyclosporin FR901459 inhibits the human P-glycoprotein and formyl peptide receptor functions.
Tiberghien F; Wenandy T; Loor F
J Antibiot (Tokyo); 2000 May; 53(5):509-15. PubMed ID: 10908115
[TBL] [Abstract][Full Text] [Related]
18. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.
Yan P; Nanamori M; Sun M; Zhou C; Cheng N; Li N; Zheng W; Xiao L; Xie X; Ye RD; Wang MW
J Immunol; 2006 Nov; 177(10):7050-8. PubMed ID: 17082621
[TBL] [Abstract][Full Text] [Related]
19. The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors.
Seifert R; Wenzel-Seifert K
Life Sci; 2003 Sep; 73(18):2263-80. PubMed ID: 12941430
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
